These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16116198)

  • 1. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge.
    Uldrich AP; Crowe NY; Kyparissoudis K; Pellicci DG; Zhan Y; Lew AM; Bouillet P; Strasser A; Smyth MJ; Godfrey DI
    J Immunol; 2005 Sep; 175(5):3092-3101. PubMed ID: 16116198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.
    Hayakawa Y; Takeda K; Yagita H; Van Kaer L; Saiki I; Okumura K
    J Immunol; 2001 May; 166(10):6012-8. PubMed ID: 11342617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
    Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
    Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors.
    Biburger M; Tiegs G
    J Leukoc Biol; 2008 Jul; 84(1):264-79. PubMed ID: 18407967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.
    Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H
    Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
    Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
    Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
    Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
    J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycolipid antigen induces long-term natural killer T cell anergy in mice.
    Parekh VV; Wilson MT; Olivares-Villagómez D; Singh AK; Wu L; Wang CR; Joyce S; Van Kaer L
    J Clin Invest; 2005 Sep; 115(9):2572-83. PubMed ID: 16138194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
    Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
    J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
    Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
    Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
    Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
    J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.
    Tomura M; Yu WG; Ahn HJ; Yamashita M; Yang YF; Ono S; Hamaoka T; Kawano T; Taniguchi M; Koezuka Y; Fujiwara H
    J Immunol; 1999 Jul; 163(1):93-101. PubMed ID: 10384104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis.
    Jin H; Carrio R; Yu A; Malek TR
    J Immunol; 2004 Jul; 173(1):657-65. PubMed ID: 15210829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
    Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
    Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
    Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
    Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-associated augmentation of the synthetic ligand- mediated function of mouse NK1.1 ag(+) T cells: their cytokine production and hepatotoxicity in vivo and in vitro.
    Inui T; Nakagawa R; Ohkura S; Habu Y; Koike Y; Motoki K; Kuranaga N; Fukasawa M; Shinomiya N; Seki S
    J Immunol; 2002 Dec; 169(11):6127-32. PubMed ID: 12444115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.
    Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL
    J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential role of LFA-1 in activating Th2-like responses by alpha-galactosylceramide-activated NKT cells.
    Matsumoto G; Kubota E; Omi Y; Lee U; Penninger JM
    J Immunol; 2004 Oct; 173(8):4976-84. PubMed ID: 15470040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia.
    Liu R; La Cava A; Bai XF; Jee Y; Price M; Campagnolo DI; Christadoss P; Vollmer TL; Van Kaer L; Shi FD
    J Immunol; 2005 Dec; 175(12):7898-904. PubMed ID: 16339525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
    Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
    J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.